TransCode Therapeutics Investor Relations Material
Latest events
AGM 2025
TransCode Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from TransCode Therapeutics Inc
Access all reports
TransCode Therapeutics Inc. is a U.S.-based biotechnology company focused on developing RNA-targeted therapies for treating cancer. The company uses its proprietary TTX platform to design and deliver RNA-based therapeutics aimed at addressing previously undruggable cancer targets. TransCode’s research primarily involves preclinical and clinical development of treatments for metastatic and solid tumors, aiming to improve precision and efficacy in cancer treatment. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
RNAZ
Country
🇺🇸 United States